{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:24:32Z","timestamp":1787509472544,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016016","name":"Gilead Sciences Europe Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jhepr.2022.100665","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T21:25:16Z","timestamp":1672176316000},"page":"100665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial)"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8853-3829","authenticated-orcid":false,"given":"Fabienne","family":"Marcellin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Mourad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Kouanfack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moussa","family":"Seydi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6794-4837","authenticated-orcid":false,"given":"Patrizia","family":"Carrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0164-7917","authenticated-orcid":false,"given":"Camelia","family":"Protopopescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8772-9029","authenticated-orcid":false,"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2022.100665_bib1","series-title":"Combating hepatitis B and C to reach elimination by 2030","year":"2016"},{"key":"10.1016\/j.jhepr.2022.100665_bib2","series-title":"Global health sector strategy on viral hepatitis 2016\u20132021 - towards\u00a0ending viral hepatitis","year":"2016"},{"key":"10.1016\/j.jhepr.2022.100665_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","article-title":"Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology commission","volume":"4","author":"Cooke","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100665_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.12.007","article-title":"Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: a systematic literature review and meta-analysis","volume":"18","author":"Zoratti","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jhepr.2022.100665_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/liv.13626","article-title":"Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in \u201cspecial populations.\u201d","volume":"38","author":"Pol","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2022.100665_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/1574887114666190306154650","article-title":"Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection","volume":"14","author":"Scotto","year":"2019","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.jhepr.2022.100665_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2471\/BLT.19.231522","article-title":"Effectiveness of generic direct-acting agents for the treatment of hepatitis C: systematic review and meta-analysis","volume":"98","author":"Perazzo","year":"2020","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jhepr.2022.100665_bib8","first-page":"259","article-title":"Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues","volume":"11","author":"Marcellin","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100665_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025415","article-title":"Screening, diagnosis and care cascade for viral hepatitis B and C in Yaound\u00e9, Cameroon: a qualitative study of patients and health providers coping with uncertainty and unbearable costs","volume":"9","author":"Chabrol","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jhepr.2022.100665_bib10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/jvh.13020","article-title":"Improving hepatitis C direct-acting antiviral access and uptake: a role for patient-reported outcomes and lived experience","volume":"26","author":"Goutzamanis","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2022.100665_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2014.09.025","article-title":"The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C","author":"Younossi","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2022.100665_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/liv.14781","article-title":"Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: results from the PROP UP study","volume":"41","author":"Serper","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2022.100665_bib13","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2169\/internalmedicine.5102-20","article-title":"Direct-acting antivirals improved the quality of life, ameliorated disease-related symptoms, and augmented muscle volume three years later in patients with hepatitis C virus","volume":"59","author":"Ichikawa","year":"2020","journal-title":"Intern Med"},{"key":"10.1016\/j.jhepr.2022.100665_bib14","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10620-020-06234-1","article-title":"Evolution of hepatitis C virus treatment during the era of sofosbuvir-based therapies: a real-world experience in France","volume":"66","author":"Ouzan","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2022.100665_bib15","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2019.04.016","article-title":"Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: the PROP UP study","volume":"71","author":"Evon","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100665_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40471-021-00273-6","article-title":"Elimination of viral hepatitis in low and middle-income countries: epidemiological research gaps","volume":"8","author":"Jaquet","year":"2021","journal-title":"Curr Epidemiol Rep"},{"key":"10.1016\/j.jhepr.2022.100665_bib17","unstructured":"Lacombe K, Moh R, Chazallon C, Lecarrou J, Sylla B, Lemoine M, et\u00a0al. Treatment of chronic hepatitis C GT1, 2, 4 in Africa: final results of ANRS 12311 TAC trial. CROI 2018 - Poster 602 - Boston, MA, USA."},{"key":"10.1016\/j.jhepr.2022.100665_bib18","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A\u00a0simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jhepr.2022.100665_bib19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jhepr.2022.100665_bib20","series-title":"SF-12v2: How to score version 2 of the SF-12 health survey","author":"Ware","year":"2002"},{"key":"10.1016\/j.jhepr.2022.100665_bib21","first-page":"677","article-title":"The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer","volume":"25","author":"Piper","year":"1998","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.jhepr.2022.100665_bib22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/hiv.12571","article-title":"Efficacy, safety and patient-reported outcomes of ledipasvir\/sofosbuvir in NS3\/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)","volume":"19","author":"Rosenthal","year":"2018","journal-title":"HIV Med"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2022.100665_bib23","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0895-4356(01)00449-8","article-title":"Development and validation of a self-completed HIV symptom index","volume":"54","author":"Justice","year":"2001","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jhepr.2022.100665_bib24","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1186\/s12885-021-08426-y","article-title":"Viral hepatitis associated hepatocellular carcinoma on the African continent, the past, present, and future: a systematic review","volume":"21","author":"Dakurah","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2022.100665_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2174\/1871526518666180716141806","article-title":"Real life Egyptian experience of daclatasvir plus sofosbuvir with ribavirin in na\u00efve difficult to treat HCV patients","volume":"20","author":"Wahsh","year":"2020","journal-title":"Infect Disord - Drug Targets"},{"key":"10.1016\/j.jhepr.2022.100665_bib26","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/jcpt.13104","article-title":"Safety, efficacy and cost of two direct-acting antiviral regimens: a comparative study in chronic hepatitis C Egyptian patients","volume":"45","author":"Ibrahim Mohammed Ebid","year":"2020","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.jhepr.2022.100665_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2468-1253(18)30382-0","article-title":"Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir\u2013sofosbuvir (SHARED): a single-arm trial","volume":"4","author":"Gupta","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100665_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103458","article-title":"Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania","volume":"99","author":"Mohamed","year":"2022","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.jhepr.2022.100665_bib29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12879-021-05920-3","article-title":"Initiation of hepatitis C treatment in two rural Rwandan districts: a mobile clinic approach","volume":"21","author":"Kamali","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100665_bib30","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/tmi.13450","article-title":"Achieving a high cure rate with direct-acting antivirals for chronic Hepatitis C virus infection in Cameroon: a multi-clinic demonstration project","volume":"25","author":"Coyer","year":"2020","journal-title":"Trop Med Int Health TM IH"},{"key":"10.1016\/j.jhepr.2022.100665_bib31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00005650-199802000-00003","article-title":"Reliability and validity of physical and mental health summary scores from the medical outcomes study HIV health survey","volume":"36","author":"Revicki","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.jhepr.2022.100665_bib32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/jvh.13386","article-title":"Improved quality of life following direct-acting antiviral treatment for chronic hepatitis C infection in Rwanda: results from a clinical trial in sub-Saharan Africa (the SHARED study)","volume":"28","author":"Van Nuil","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2022.100665_bib33","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1023\/B:QURE.0000040797.17449.c0","article-title":"The liver disease symptom index 2.0; validation of a disease-specific questionnaire","volume":"13","author":"van der Plas","year":"2004","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jhepr.2022.100665_bib34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12876-017-0581-1","article-title":"Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt","volume":"17","author":"Youssef","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100665_bib35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40121-018-0208-z","article-title":"The impact of hepatitis C virus direct-acting antivirals on patient-reported outcomes: a Dutch prospective cohort study","volume":"7","author":"Kracht","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jhepr.2022.100665_bib36","doi-asserted-by":"crossref","first-page":"ofaa317","DOI":"10.1093\/ofid\/ofaa317","article-title":"Clinical and patient-reported outcomes of direct-acting antivirals for the treatment of chronic hepatitis C among patients on opioid agonist treatment: a real-world prospective cohort study","volume":"7","author":"Schulte","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100665_bib37","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jval.2018.01.006","article-title":"French patients with hepatitis C treated with direct-acting antiviral combinations: the effect on patient-reported outcomes","volume":"21","author":"Cacoub","year":"2018","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"10.1016\/j.jhepr.2022.100665_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237005","article-title":"Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free","volume":"15","author":"Fagundes","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2022.100665_bib39","first-page":"1093.e5","article-title":"Patient-reported outcomes of sleep, mood and quality of life after treatment of chronic hepatitis C infection using direct-acting antiviral agents","volume":"26","author":"Karimi-Sari","year":"2020","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100665_bib40","doi-asserted-by":"crossref","first-page":"A471","DOI":"10.1016\/j.jval.2016.09.724","article-title":"A\u00a0cross-national comparison of the effect of age and gender on health-related quality of life (Hrql)","volume":"19","author":"Rendas-Baum","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.jhepr.2022.100665_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2019.10.019","article-title":"Patient-reported symptoms during direct-acting antiviral treatment: a real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)","author":"Marcellin","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100665_bib42","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/jvh.13234","article-title":"Hepatitis C cure improved patient-reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban medical center","volume":"27","author":"Sung","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2022.100665_bib43","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/MEG.0000000000000883","article-title":"Short article: anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH)","volume":"29","author":"Marcellin","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100665_bib44","first-page":"402","article-title":"Male sexual dysfunction among\u00a0Egyptian patients with chronic hepatitis C virus infection before\u00a0and after direct-acting antiviral drugs","volume":"16","author":"Elshimi","year":"2019","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.jhepr.2022.100665_bib45","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/MEG.0000000000000664","article-title":"Short article: fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon\/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort)","volume":"28","author":"Marcellin","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100665_bib46","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v27.i29.4846","article-title":"Neurological and psychiatric effects of hepatitis C virus infection","volume":"27","author":"Faccioli","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100665_bib47","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cgh.2019.07.047","article-title":"Long-term benefits of sustained virologic response for patient-reported outcomes in patients with chronic hepatitis C virus infection","volume":"18","author":"Younossi","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100665_bib48","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jhep.2014.04.003","article-title":"Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study","volume":"61","author":"Younossi","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhepr.2022.100665_bib49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/heapol\/czr039","article-title":"Performance of HIV care decentralization from the patient\u2019s perspective: health-related quality of life and perceived quality of services in Cameroon","volume":"27","author":"Boyer","year":"2012","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.jhepr.2022.100665_bib50","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3389\/fphar.2017.00919","article-title":"Association between health-related quality of life and medication adherence in pulmonary tuberculosis in South Africa","volume":"8","author":"Kastien-Hilka","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhepr.2022.100665_bib51","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/tmi.13089","article-title":"Birthing experience and quality of life after vacuum delivery and second-stage caesarean section: a prospective cohort study in Uganda","volume":"23","author":"Nolens","year":"2018","journal-title":"Trop Med Int Health TM IH"},{"key":"10.1016\/j.jhepr.2022.100665_bib52","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/09540121.2017.1417970","article-title":"Gender differences in health-related quality of life at the time of a positive HIV test - a cross-sectional study in a resource-poor, high prevalence setting in Nairobi, Kenya","volume":"30","author":"van der Kop","year":"2018","journal-title":"AIDS Care"},{"key":"10.1016\/j.jhepr.2022.100665_bib53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.drugpo.2016.03.005","article-title":"Improvements in health-related quality of life among methadone maintenance clients in Dar es Salaam, Tanzania","volume":"30","author":"Ubuguyu","year":"2016","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.jhepr.2022.100665_bib54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12955-017-0708-7","article-title":"The validity of the SF-12 and SF-6D instruments in people living with HIV\/AIDS in Kenya","volume":"15","author":"Patel","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jhepr.2022.100665_bib55","doi-asserted-by":"crossref","unstructured":"Protopopescu C., Boyer S., Marcellin F., Carrieri M.P., Koulla-Shiro S., Spire B. Validation de l\u2019\u00e9chelle de qualit\u00e9 de vie SF12 chez des patients infect\u00e9s par le VIH au Cameroun (enqu\u00eate EVAL\u2013ANRS 12-116) [in French]. Revue d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique 2011; 59 (S1):S9.","DOI":"10.1016\/j.respe.2011.02.074"},{"key":"10.1016\/j.jhepr.2022.100665_bib56","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555922002373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555922002373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:30:32Z","timestamp":1762900232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555922002373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2589555922002373"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100665","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial)","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100665"}}